TY - JOUR
T1 - Neuronal correlates of appetite regulation in patients with schizophrenia
T2 - Is there a basis for future appetite dysfunction?
AU - Lungu, O.
AU - Anselmo, K.
AU - Letourneau, G.
AU - Mendrek, A.
AU - Stip, B.
AU - Lipp, O.
AU - Lalonde, P.
AU - Ait Bentaleb, L.
AU - Stip, E.
N1 - Funding Information:
This study was conducted as part of investigator initiated trials (N o : clinical trial: NCT 00290121 ) funded by Eli Lilly Canada.
PY - 2013/6
Y1 - 2013/6
N2 - Background: Given the undesired metabolic side effects of atypical antipsychotic medication it is important to understand the neuronal basis related to processing of appetite regulation in patients affected by schizophrenia. Methods: Here we used functional magnetic resonance imaging (fMRI) to assess brain activity in response to food cues and neutral stimuli in twenty patients with schizophrenia and eleven healthy individuals. In addition to clinical and dietary habits assessments, we collected, in patients, measurements of fasting glucose, ghrelin, leptin, insulin, prolactin and lipids blood concentration and we correlated the cerebral activity with clinical and metabolic measures. Results: Both groups engaged a common neuronal network while processing food cues, which included the left insula, primary sensorimotor areas, and inferior temporal and parietal cortices. Cerebral responses to appetitive stimuli in thalamus, parahippocampus and middle frontal gyri were specific only to schizophrenic patients, with parahippocampal activity related to hunger state and increasing linearly over time. Antipsychotic medication dosage correlated positively with a cognitive measure reflecting food cravings, whereas the severity of the disease correlated negatively with a cognitive measure indicating dietary restraint in eating habits. These cognitive variables correlated, in turn, with parahippocampal and thalamic neuronal activities, respectively. Conclusions: We identified a specific neural substrate underlying cognitive processing of appetitive stimuli in schizophrenia, which may contribute to appetite dysfunction via perturbations in processing of homeostatic signals in relation to external stimuli. Our results also suggest that both antipsychotic medication and the disease severity per se could amplify these effects, via different mechanisms and neuronal networks.
AB - Background: Given the undesired metabolic side effects of atypical antipsychotic medication it is important to understand the neuronal basis related to processing of appetite regulation in patients affected by schizophrenia. Methods: Here we used functional magnetic resonance imaging (fMRI) to assess brain activity in response to food cues and neutral stimuli in twenty patients with schizophrenia and eleven healthy individuals. In addition to clinical and dietary habits assessments, we collected, in patients, measurements of fasting glucose, ghrelin, leptin, insulin, prolactin and lipids blood concentration and we correlated the cerebral activity with clinical and metabolic measures. Results: Both groups engaged a common neuronal network while processing food cues, which included the left insula, primary sensorimotor areas, and inferior temporal and parietal cortices. Cerebral responses to appetitive stimuli in thalamus, parahippocampus and middle frontal gyri were specific only to schizophrenic patients, with parahippocampal activity related to hunger state and increasing linearly over time. Antipsychotic medication dosage correlated positively with a cognitive measure reflecting food cravings, whereas the severity of the disease correlated negatively with a cognitive measure indicating dietary restraint in eating habits. These cognitive variables correlated, in turn, with parahippocampal and thalamic neuronal activities, respectively. Conclusions: We identified a specific neural substrate underlying cognitive processing of appetitive stimuli in schizophrenia, which may contribute to appetite dysfunction via perturbations in processing of homeostatic signals in relation to external stimuli. Our results also suggest that both antipsychotic medication and the disease severity per se could amplify these effects, via different mechanisms and neuronal networks.
KW - Antipsychotics
KW - Binge eating disorder
KW - FMRI
KW - Schizophrenia and psychosis
UR - http://www.scopus.com/inward/record.url?scp=84878913113&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878913113&partnerID=8YFLogxK
U2 - 10.1016/j.eurpsy.2012.02.001
DO - 10.1016/j.eurpsy.2012.02.001
M3 - Article
C2 - 22542330
AN - SCOPUS:84878913113
SN - 0924-9338
VL - 28
SP - 293
EP - 301
JO - European Psychiatry
JF - European Psychiatry
IS - 5
ER -